Hosted on MSN

Google confirms first AI-built zero-day exploit blocked

First AI zero-day: Google detected the first confirmed AI-created zero-day exploit, aimed at bypassing 2FA in a popular ...
Hosted on MSN

Google blocks first AI-built zero-day exploit before mass attack

AI breach attempt: Google detected hackers using AI to create a zero-day exploit targeting two-factor authentication in a widely used open-source admin tool. Mass attack foiled: The planned ...
cryptopolitan

Google catches first zero-day exploit built with AI assistance

Google found the first known zero-day exploit it believes was built using AI. The exploit targets two-factor authentication (2FA) on an open-source admin tool. State sponsored hackers from China and ...
The Hacker News

Hackers Used AI to Develop First Known Zero-Day 2FA Bypass for Mass Exploitation

Google identified the first malicious AI use for a zero-day 2FA bypass in an open-source admin tool, accelerating threat ...

Google says criminals used AI to build a working zero-day exploit for the first time

Criminal hackers have used artificial intelligence to develop a working zero-day exploit, the first confirmed case of its ...
Forbes

Generate Biomedicines IPO Turns Heads

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Reuters

Generate Biomedicines shares fall in weak Nasdaq debut for drug developer

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
MedCity News

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
Reuters

Drug developer Generate Biomedicines raises $400 million in US IPO

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...
The Boston Globe

Flagship-backed Generate Biomedicines seeks $425 million in IPO

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
GitHub

Automatically generate Python docstrings using ChatGPT.

To use the extension, you need an API key from OpenAI or another OpenAI-compatible provider. How to Set or Change API Key When you first generate a docstring, a pop-up window will appear requesting ...
Seeking Alpha

Generate Biomedicines Begins IPO Push With Major Collaboration Deals

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...